Preservative-Free Tafluprost/Timolol Fixed Combo Reduces IOP in Open-Angle Glaucoma

Pavankumar Kamat

Disclosures

April 28, 2021

Takeaway

  • Preservative-free tafluprost (0.0015%)/timolol (0.5%) fixed combination (PF-Taf-T-FC) was effective in reducing intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT), inadequately controlled on prior monotherapies with prostaglandin analogues (PGAs) or beta-blockers.

  • PF-Taf-T-FC was well-tolerated with mostly mild-to-moderate adverse events (AEs).

Why this matters

  • Findings highlight the real-world efficacy of PF-Taf-T-FC in improving IOP, the only modifiable risk factor for OAG.

Study details

  • This study reported results from UK (n=65) and Ireland cohorts (n=17) enrolled in the VISIONARY trial evaluating the effectiveness of PF-Taf-T-FC in patients with OAG or OHT inadequately managed by PGA or beta-blocker monotherapies.

  • Primary endpoint: change in IOP from baseline to 6 months.

  • Funding: Santen SA.

Key results

  • PF-Taf-T-FC treatment significantly reduced IOP (mean±standard deviation [SD]) at 6 months:

  • UK cohort: 22.0±4.5 (baseline) to 16.2±2.9 mmHg (month 6); P<.0001; and

  • Ireland cohort: 18.6±5.1 (baseline) to 14.1±3.0 mmHg (month 6); P=.003.

  • Significant IOP reduction (P<.0001) was seen from week 4 (mean±SD, 17.2±3.6 mmHg) of treatment in the UK cohort.

  • In the UK cohort, 49 AEs (mild, 63.3%; moderate, 26.5%; severe, 10.2%) were reported, of which 46.9% were treatment-related.

  • No AEs were reported in the Ireland cohort.

  • After 6 months of therapy, 90% of patients reported good or very good tolerability with PF-Taf-T-FC.

Limitations

  • Small sample size.

  • Results not applicable to angle-closure and childhood glaucomas.

 

Ansari E, Pavicic-Astalos J, Ayan F, King AJ, Kinsella M, Ng E, Nita A; VISIONARY Group. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study. Adv Ther. 2021 Apr 22 [Epub ahead of print]. doi: 10.1007/s12325-021-01725-7. PMID: 33886093. View full text

This clinical summary originally appeared on Univadis, part of the Medscape Professional Network.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....